Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors.
Simple Summary: Patients treated with BTK inhibitors frequently demonstrate dermatologic toxicities, such as bruising, rash, infections, mucosal symptoms, neutrophilic dermatoses, vasculitis, infections, nail plate abnormalities and hair changes. In most cases, skin toxicities remain mild. Proactive...
| Published in: | Cancers Vol. 18; no. 3; pp. 371 - 389 |
|---|---|
| Main Authors: | , |
| Format: | pictorial review Journal Article |
| Published: |
MDPI
Feb2026
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191587954&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191587954 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726694 B74B jtl: Cancers issn: 20726694 maglogo: N pubinfo: dt: Feb2026 vid: 18 iid: 3 pid: 97109 pub: MDPI artinfo: ui: 191587954 191587954 191587954 10.3390/cancers18030371 191587954 ppf: 371 ppct: 18 formats: tig: atl: Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors. aug: au: Robak, Ewa Robak, Tadeusz affil: Department of Dermatology, Medical University of Lodz, 90-647 Łódź, Poland sug: subj: Tyrosine Kinase Inhibitors Adverse Effects Antineoplastic Agents Adverse Effects Skin Manifestations Pathology Skin Manifestations Symptoms Skin Pathology Hemorrhage Symptoms Purpura Hematoma Exanthema Vasculitis Sweet's Syndrome Panniculitis Pyoderma Gangrenosum Skin Infection Nails Pathology Hair Abnormalities ab: Simple Summary: Patients treated with BTK inhibitors frequently demonstrate dermatologic toxicities, such as bruising, rash, infections, mucosal symptoms, neutrophilic dermatoses, vasculitis, infections, nail plate abnormalities and hair changes. In most cases, skin toxicities remain mild. Proactive management is crucial in order to limit dose-intensity modification. For most patients, these skin changes are benign and do not require treatment: discontinuation or topical or oral corticosteroid use should be considered until cutaneous symptoms disappear. However, in some patients, BTKi dose reduction, treatment interruption, or even cessation of treatment is recommended. Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for patients with indolent lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The most common adverse events include cardiac arrhythmia, bleeding, infection, diarrhea, arthralgias, hypertension, and skin changes. Second-generation BTK inhibitors, e.g., acalabrutinib and zanubrutinib and the non-covalent BTK inhibitor pirtobrutinib, are less toxic than the first-generation BTK inhibitor ibrutinib. The most common toxic skin symptoms related to BTKi treatment include hemorrhage, bleeding events, bruising, skin ecchymoses, and contusion; they are particularly common in patients treated with ibrutinib. Other dermatologic symptoms include rash, cellulitis, skin infections, subcutaneous abscesses and peripheral edema. This article discusses the development of skin symptoms in patients with ibrutinib and newer BTK inhibitors, and summarizes their clinical and pathological characteristics. A literature search was performed using PubMed, Web of Science, and Google Scholar for articles published in English. Additional relevant publications were obtained by reviewing the references from the chosen articles. pubtype: Academic Journal doctype: pictorial review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|